“肺炎”概念股炒作降温 資金正進行去偽存真
格隆匯1月22日丨A股市場今日盤中對“肺炎”概念股的炒作有明顯降温,如醫藥類股海王生物、東北製藥、華潤三九和白雲山等衝高回落,口罩股際華集團、南衞股份、金鷹股份、申達股份等衝高回落,澄清無口罩業務的龍頭股份大跌。詳情可上格隆匯APP搜索肺炎和口罩主題查看相關股票池。由此可見,市場資金已從一開始的“瘋狂炒作”正逐步去偽純真。官方數據稱,截至1月22日10時,我國共確診440例新型冠狀病毒感染的肺炎病例,其中死亡9例。截至目前,下午又有多地公佈了新增的新型肺炎確診病例數據。詳情可點擊鏈接:https://m.gelonghui.com/subject/663?from=singlemessage
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.